Drug name - Vyleesi (autoinjector)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6794489 PALATIN TECHNOLOGIES Compositions and methods for treatment of sexual dysfunction
Jun, 2025

(2 years from now)

CN1988915A PALATIN TECHNOLOGIES Multiple Agent Therapy For Sexual Dysfunction
Feb, 2010

(12 years ago)

CN101010095A PALATIN TECHNOLOGIES Cyclic Peptide For Treating Cachexia
Apr, 2011

(11 years ago)

CN101010096A PALATIN TECHNOLOGIES Cyclic Peptide For Treating Cachexia
Apr, 2011

(11 years ago)

EP1196184B8 PALATIN TECHNOLOGIES Compositions For Treatment Of Sexual Dysfunction
Jun, 2020

(2 years ago)

EP1196184A4 PALATIN TECHNOLOGIES Compositions And Methods For Treatment Of Sexual Dysfunction
Jun, 2020

(2 years ago)

EP1196184B1 PALATIN TECHNOLOGIES Compositions For Treatment Of Sexual Dysfunction
Jun, 2020

(2 years ago)

EP1196184A1 PALATIN TECHNOLOGIES Compositions For Treatment Of Sexual Dysfunction
Jun, 2020

(2 years ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9352013 PALATIN TECHNOLOGIES Uses of bremelanotide in therapy for female sexual dysfunction Nov, 2033

(11 years from now)

US9700592 PALATIN TECHNOLOGIES Uses of bremelanotide in therapy for female sexual dysfunction Nov, 2033

(11 years from now)

US10286034 PALATIN TECHNOLOGIES Uses of bremelanotide in therapy for female sexual dysfunction Nov, 2033

(11 years from now)

Drugs and Companies using BREMELANOTIDE ACETATE ingredient

Treatment: Treatment of hypoactive sexual desire disorder (hsdd)

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML) SOLUTION;SUBCUTANEOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.